In vivo evidence for microglial activation in neurodegenerative dementia
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Evidence from numerous neuropathological observations and in vivo clinical imaging studies suggests a prominent role of activated microglia, the main effector cell of the brain's innate immune system, in Alzheimer's disease and other neurodegenerative diseases. Though the comprehensive molecular definition of the microglial activation process is still incomplete, the de novo expression of 'peripheral benzodiazepine-binding sites (PBBS)' by activated but not resting microglia has been established as a useful descriptor of functional state changes in microglia. As microglial transformation to an activated state is closely linked to progressive changes in brain disease, the detection of activated microglia can provide information about disease distribution and rate of disease progression. Positron emission tomography (PET) and [(11)C](R)-PK11195, a specific ligand of the PBBS, have been used to study systematically microglial activation in vivo. Significant microglial activation is present in the brains of patients with neurodegenerative dementia even at early and possibly preclinical stages of the disease with a spatial distribution reflecting different clinical phenotypes. We review some of the posited functions of activated microglia in the pathophysiology of dementia and speculate on the relationship between increased regional [(11)C](R)-PK11195 signals and the ensuing changes in brain volume. Finally, we provide a brief outlook on the development of new radioligands for the PBBS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235 · cited 1×
“A similar finding has also been made in transgenic mice over-expressing both APP and an inhibitor of the complement C3 leading to a more pronounced Ab plaque burden and neuronal loss (56).”
BackgroundIn vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Self-citationNonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
In-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 1×
“In addition, combining the [(11)C](R)-PK11195 PET study with a PET scan using (18)FDG tracer in the same AD patients, we found a correspondence between the regions with increased [(11)C](R)-PK11195 binding and the regions with glucose hypometabolism (31).”
MethodSelf-citationLiberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046 · cited 1×
“Several experimental animal studies and postmortem studies support a causal relationship between processes induced by inflammatory mechanisms, such as oxidative toxicity and neuronal death and degeneration (38, 44).”
BackgroundMicroglia as neuroprotective, immunocompetent cells of the CNS
Streit, W. J. (2002) · Glia · doi:10.1002/glia.10154 · Cited by 919
Turner, M. R., Cagnin, A., Turkheimer, F. E., Miller, C. C. J., Shaw, C. E., Brooks, D. J., Leigh, P. N., & Banati, R. B. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.012 · Cited by 737
Self-citation
Cited by
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
Wang, Q., Liu, Y., & Zhou, J. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0042-0 · Cited by 884
“It has been proposed that activated microglia may be beneficial to the host, at least in the early phase of neurodegeneration process [12, 32–34].”
BackgroundCytokines and schizophrenia: microglia hypothesis of schizophrenia
Monji, A., Kato, T., & Kanba, S. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.01945.x · Cited by 508
Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 423
Kynurenines in CNS disease: regulation by inflammatory cytokines.
Campbell, B. M., Charych, E., Lee, A. W., & Möller, T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00012 · Cited by 409
Pathophysiological Role of Neuroinflammation in Neurodegenerative Diseases and Psychiatric Disorders
Hong, H., Kim, B. S., & Im, H.-I. (2016) · International Neurourology Journal · doi:10.5213/inj.1632604.302 · Cited by 258
The 18 kDa Translocator Protein, Microglia and Neuroinflammation
Liu, G., Middleton, R. J., Hatty, C. R., Kam, W. W., Chan, R., Pham, T., Harrison‐Brown, M., Dodson, E., Veale, K., & Banati, R. B. (2014) · Brain Pathology · doi:10.1111/bpa.12196 · Cited by 211
“Increased binding of ligands selective for TSPO has been observed at sites of central nervous system (CNS) pathology, such as glioma (162, 165, 166, 179), multiple sclerosis (21) as well as Alzheimer’s disease (AD) (38), and TSPO ligand binding is now seen as a hallmark for microglial activation in vivo.”
BackgroundSelf-citationAnthony, I. C., Norrby, K. E., Dingwall, T., Carnie, F. W., Millar, T., Arango, J. C., Robertson, R., & Bell, J. E. (2010) · Brain · doi:10.1093/brain/awq263 · Cited by 156
Agosta, F., Dalla Libera, D., Spinelli, E. G., Finardi, A., Canu, E., Bergami, A., Bocchio Chiavetto, L., Baronio, M., Comi, G., Martino, G., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24235 · Cited by 113
Patterns of microglial cell activation in frontotemporal lobar degeneration
Lant, S. B., Robinson, A. C., Thompson, J. C., Rollinson, S., Pickering‐Brown, S., Snowden, J. S., Davidson, Y. S., Gerhard, A., & Mann, D. M. A. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12092 · Cited by 102
“microglial and astrocytic in origin, in neurodegenerative disease [34-36].”
BackgroundThe Therapeutic Role of Minocycline in Parkinson’s Disease
Cankaya, S., Cankaya, B., Kilic, U., Kilic, E., & Yulug, B. (2019) · Drugs in Context · doi:10.7573/dic.212553 · Cited by 93
Microglia: Friend and foe in tauopathy
Odfalk, K. F., Bieniek, K. F., & Hopp, S. C. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102306 · Cited by 60
Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging
Zhang, J. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0236-5 · Cited by 62
“It has been reported that PET imaging with the widely used first-generation TSPO ligand [11C]-PK11195 detected neuroinflammation in patients with mild cognitive impairment (MCI) [21].”
MethodInfluential
Metadata
- Authors
- Cagnin, A., Kassiou, M., Meikle, S. R., & Banati, R. B.
- Venue
- Acta Neurologica Scandinavica
- Publisher
- Wiley
- Published
- 2006-08
- Volume
- 114
- Issue
- s185
- Pages
- 107-114
- ISSN
- 0001-6314 (ISSN-L)
- 1600-0404
- OpenAlex
- W2024627685
- Cited by
- 71
- References
- 23
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.